Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles

Kuo, Yung‐Chih; Chen, Yu‐Chun

doi:10.1016/j.ijpharm.2014.12.070

Cited by 88 publications

(43 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, Lf was found efficient in the specific targeting of central nervous system (CNS) by overcoming blood-brain barrier (BBB) [206][207][208][209]. As a matter of fact, one of the most critical limitation for the treatment of CNS pathologies, including cancer, is represented by BBB which restricts the delivery of therapeutic agents to the brain.…”

Section: Lactoferrin As a Cargo For Cancer Targetingmentioning

confidence: 99%

“…The use of Lf as carrier for CNS treatment is due to the high expression of LRP1 on cells constituting BBB and even more on glioma cells, the most recurrent type of cancer in the brain [66,210]. Overall, studies employing Lf-bearing NPs co-loaded with different type of chemotherapeutics in the treatment of glioblastoma reported a good safety profile, an enhanced permeation of BBB and efficient drug delivery to glioma cells [206][207][208][209].…”

Section: Lactoferrin As a Cargo For Cancer Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Lactoferrin’s Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action

et al. 2020

View full text Add to dashboard Cite

Despite recent advances in cancer therapy, current treatments, including radiotherapy, chemotherapy, and immunotherapy, although beneficial, present attendant side effects and long-term sequelae, usually more or less affecting quality of life of the patients. Indeed, except for most of the immunotherapeutic agents, the complete lack of selectivity between normal and cancer cells for radioand chemotherapy can make them potential antagonists of the host anti-cancer self-defense over time. Recently, the use of nutraceuticals as natural compounds corroborating anti-cancer standard therapy is emerging as a promising tool for their relative abundance, bioavailability, safety, low-cost effectiveness, and immuno-compatibility with the host. In this review, we outlined the anti-cancer properties of Lactoferrin (Lf), an iron-binding glycoprotein of the innate immune defense. Lf shows high bioavailability after oral administration, high selectivity toward cancer cells, and a wide range of molecular targets controlling tumor proliferation, survival, migration, invasion, and metastasization. Of note, Lf is able to promote or inhibit cell proliferation and migration depending on whether it acts upon normal or cancerous cells, respectively. Importantly, Lf administration is highly tolerated and does not present significant adverse effects. Moreover, Lf can prevent development or inhibit cancer growth by boosting adaptive immune response. Finally, Lf was recently found to be an ideal carrier for chemotherapeutics, even for the treatment of brain tumors due to its ability to cross the blood-brain barrier, thus globally appearing as a promising tool for cancer prevention and treatment, especially in combination therapies.

show abstract

Section: Lactoferrin As a Cargo For Cancer Targetingmentioning

confidence: 99%

Section: Lactoferrin As a Cargo For Cancer Targetingmentioning

confidence: 99%

Lactoferrin’s Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In a report by Kuo and Chen (), the lactoferrin (Lf)‐ and FA‐grafted PLGA NPs (Lf/FA/PLGA NPs; 181.9 ± 4.5 nm particle size with positive surface charge) were developed for targeted delivery of etoposide to inhibit the Glioblastoma (GBM) growth and penetrate in monolayer of human brain‐microvascular endothelial cells (HBMECs). The Lf has been applied to permeate an in vitro blood–brain barrier (BBB) via receptor‐mediated transcytosis (RMT) (Huang et al, ).…”

Section: Polymer‐based Nps In Drug Deliverymentioning

confidence: 99%

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Narmani

Rezvani

Farhood

et al. 2019

Drug Development Research

152

View full text Add to dashboard Cite

Conventional chemotherapeutic approaches in cancer therapy such as surgery, chemotherapy, and radiotherapy have several disadvantages due to their nontargeted distributions in the whole body. On the other hand, nanoparticles (NPs) based therapies are remarkably progressing to solve several limitations of conventional drug delivery systems (DDSs) including nonspecific biodistribution and targeting, poor water solubility, weak bioavailability and biodegradability, low pharmacokinetic properties, and so forth. The enhanced permeability and retention effect escape from Pglycoprotein trap in cancer cells as a passive targeting mechanism, and active targeting strategies are also other most important advantages of NPs in cancer diagnosis and therapy. Folic acid (FA) is one of the biologic molecules which has been targeted overexpressed-folic acid receptor (FR) on the surface of cancer cells. Therefore, conjugation of FA to NPs most easily enhances the FR-mediated targeting delivery of therapeutic agents. Here, the recent works in FA which have been decorated NPs-based DDSs are discussed and cancer therapy potency of these NPs in clinical trials are presented. K E Y W O R D Scancer diagnosis and therapy, folic acid, nanoparticles, nanotechnology, targeted drug delivery

show abstract

“…18,19 It was reported that Lf could benefit the transport of anticancer medicine-loaded polymeric nanoparticles to brain tumor. 20 Thus, RMP-7 and Lf may qualify as ingredients in pharmaceutical formulations for AD medication. Furthermore, the combined use of RMP-7 with Lf in brain targeting has never been reported.…”

Section: Introductionmentioning

confidence: 99%

Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin

Kuo

Tsao

2017

IJN

Self Cite

View full text Add to dashboard Cite

A drug delivery system of quercetin (QU)-encapsulated liposomes (LS) grafted with RMP-7, a bradykinin analog, and lactoferrin (Lf) was developed to permeate the blood–brain barrier (BBB) and rescue degenerated neurons, acting as an Alzheimer’s disease (AD) pharmacotherapy. This colloidal formulation of QU-encapsulated LS grafted with RMP-7 and Lf (RMP-7-Lf-QU-LS) was used to traverse human brain microvascular endothelial cells (HBMECs) regulated by human astrocytes (HAs) and to treat SK-N-MC cells after an insult with cytotoxic β-amyloid (Aβ) fibrils. We found that surface RMP-7 and Lf enhanced the ability of QU to cross the BBB without inducing strong toxicity and damaging the tight junction. In addition, RMP-7-Lf-QU-LS significantly reduced Aβ-induced neurotoxicity and improved the viability of SK-N-MC cells. Compared with free QU, RMP-7-Lf-QU-LS could also significantly inhibit the expression of phosphorylated c-Jun N terminal kinase, phosphorylated p38, and phosphorylated tau protein at serine 202 by SK-N-MC cells, indicating an important role of RMP-7, Lf, and LS in protecting neurons against apoptosis. RMP-7-Lf-QU-LS is a promising carrier targeting the BBB to prevent Aβ-insulted neurodegeneration and may have potential in managing AD in future clinical applications.

show abstract

Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles

Cited by 88 publications

References 42 publications

Lactoferrin’s Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action

Lactoferrin’s Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin

Contact Info

Product

Resources

About